| Politician | Action | Description | Traded |
|---|---|---|---|
| Sell | Alnylam Pharmaceuticals, Inc | Aug 11, 2026 | |
| Sell | ALNYLAM THERAPEUTICS | May 15, 2026 | |
| Buy | ALNYLAM PHARMACEUTICALS INCO | Jan 26, 2026 | |
| Sell | ALNYLAM PHARMACEUTICALS | Oct 30, 2025 | |
| Sell | Alnylam Pharmaceuticals, Inc | May 12, 2025 | |
| Buy | ALNYLAM PHARMACEUTICALS, INC | Feb 19, 2025 | |
| Buy | ALNYLAM PHARMACEUTICALS INC | Jan 29, 2025 | |
| Buy | ALNYLAM PHARMACEUTICALS INC | Jul 2, 2024 | |
| Sell | Alnylam Pharmaceuticals, Inc | Jan 29, 2024 | |
| Buy | Alnylam Pharmaceuticals, Inc | Jan 11, 2024 |
This page tracks congressional stock trading activity in Alnylam Pharmaceuticals, Inc. (ALNY) in the Healthcare sector. Disclosed Capitol has indexed 37 disclosed congressional trades involving ALNY. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of September 2026 — Disclosed Capitol has tracked 37 disclosed congressional trades in Alnylam Pharmaceuticals, Inc. (ALNY) — 14:11 sell-heavy ratio — led by Ro Khanna (D).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Aug 11, 2026 | Cory A Booker | D | Sell | $1,001 - $15,000 |
| May 15, 2026 | Michael McCaul | R | Sell | $15,001 - $50,000 |
| Jan 26, 2026 | Michael McCaul | R | Buy | $15,001 - $50,000 |
| Oct 30, 2025 | Michael McCaul | R | Sale | $50,001 - $100,000 |
| May 12, 2025 | Jefferson Shreve | R | Sale | $15,001 - $50,000 |
| Feb 19, 2025 | Ro Khanna | D | Purchase | $1,001 - $15,000 |
| Jan 29, 2025 | Ro Khanna | D | Purchase | $1,001 - $15,000 |
| Jul 2, 2024 | Ro Khanna | D | Purchase | $1,001 - $15,000 |
| Jan 29, 2024 | Josh Gottheimer | D | Sale | $1,001 - $15,000 |
| Jan 11, 2024 | Josh Gottheimer | D | Buy | $1,001 - $15,000 |
Across the 37 disclosed congressional trades in Alnylam Pharmaceuticals, Inc. (ALNY), members of Congress have reported 11 buys and 14 sells. The average 30-day alpha vs. the S&P 500 is 2.55%.
For fiscal year 2025, Alnylam Pharmaceuticals, Inc. reported revenue of $3.71B and net income of $313.7M, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $2.46B, net income $370.5M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.